Saving and Improving
Patients' Lives
Saving and Improving
Patients' Lives
Our Story
Motivated by our purpose of “saving and improving patients’ lives”, Piramal Critical Care marked its entry in the field of inhalation anesthetics in 2002 with the acquisition of ICI India Ltd. Since then, we have established our name as a global anesthetic company with much of our growth developed through acquisitions of trusted and established manufacturers.
Acquisition of pharmaceuticals business of ICI India Limited
Acquisition of Minrad Inc., United States
Acquisition of Injectable Anesthesia business of BSV, India
Acquired distribution license for injectable antibacterials such as Ampicillin and Sulbactam for Injection, USP, Cefepime for Injection, USP, Ceftriaxone for Injection, USP and Ampicillin for Injection, USP.
Started marketing Glycopyrrolate Injection, USP manufactured at a CMO facility in India.
PCC licensed Linezolid Injection.
Acquired distribution license for injectable antibacterial such as Piperacillin and Tazobactam for Injection, USP.
Acquired distribution license for Rocuronium Bromide Injection.
Acquired distribution license for Succinylcholine Chloride Injection, USP, Dexmedetomidine Injection, USP and Dexmedetomidine HCl in 0.9% Sodium Chloride Injection (RTU*).
*Ready to use.
Values
KNOWLEDGE
Expertise
Innovation
ACTION
Entrepreneurship
Integrity
CARE
Trusteeship
Humility
IMPACT
Performance
Resilience
Piramal Critical Care
Find. Read. Learn
News & Events
Learn more about upcoming events, new press releases, and the latest news from Piramal Critical Care.
Contact & Support
